Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Ascending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
69189-0679-01 69189-0679 Dolasetron mesylate Anzemet 100.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 26, 2016 May 24, 2017 No Longer Used
65219-0029-20 65219-0029 Thiotepa Thiotepa 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical April 11, 2022 In Use
68180-0390-09 68180-0390 IMATINIB IMATINIB MESYLATE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral July 8, 2019 In Use
72064-0210-12 72064-0210 pralsetinib GAVRETO 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sept. 4, 2020 April 30, 2022 No Longer Used
72064-0210-60 72064-0210 pralsetinib GAVRETO 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sept. 4, 2020 April 30, 2022 No Longer Used
72064-0210-90 72064-0210 pralsetinib GAVRETO 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sept. 4, 2020 April 30, 2022 No Longer Used
50268-0426-12 50268-0426 Imatinib Mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug. 24, 2017 In Use
00074-0576-11 00074-0576 Venetoclax Venclexta 100.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral April 11, 2016 In Use
00074-0576-22 00074-0576 Venetoclax Venclexta 100.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral April 11, 2016 In Use
00074-0576-30 00074-0576 Venetoclax Venclexta 100.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral June 15, 2022 In Use
00074-0576-34 00074-0576 Venetoclax Venclexta 100.0 mg/1 Chemotherapy Enzyme Inhibitor BCL-2 Oral Nov. 21, 2018 In Use
59651-0531-03 59651-0531 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
59651-0531-10 59651-0531 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 22, 2022 In Use
67184-0532-01 67184-0532 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use
67184-0532-02 67184-0532 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use
67184-0532-03 67184-0532 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 21, 2022 In Use
63539-0117-01 63539-0117 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00310-3512-60 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug. 4, 2022 In Use
00310-3512-95 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug. 4, 2022 In Use
64380-0129-02 64380-0129 Cyclosporine Cyclosporine 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral Aug. 16, 2022 In Use
72819-0185-09 72819-0185 Imatinib mesylate Imatinib mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2022 In Use
67457-0254-30 67457-0254 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous May 23, 2016 In Use
16571-0818-02 16571-0818 Temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0818-51 16571-0818 Temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16571-0818-41 16571-0818 Temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 4, 2022 In Use
16714-0578-01 16714-0578 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Nov. 18, 2022 In Use
43598-0171-11 43598-0171 Thiotepa Thiotepa 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical Nov. 1, 2022 In Use
00378-7132-93 00378-7132 erlotinib hydrochloride Erlotinib Hydrochloride 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 Nov. 30, 2022 No Longer Used
00781-3253-94 00781-3253 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sept. 16, 2013 Feb. 28, 2025 In Use
10019-0079-01 10019-0079 Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 15, 2022 In Use
60505-0134-00 60505-0134 Cyclosporine Cyclosporine 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral May 29, 2002 In Use
60505-0134-01 60505-0134 Cyclosporine Cyclosporine 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral May 29, 2002 Dec. 31, 2022 In Use
60505-0134-02 60505-0134 Cyclosporine Cyclosporine 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral May 29, 2002 Dec. 31, 2022 In Use
46708-0566-30 46708-0566 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
46708-0566-90 46708-0566 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
58181-3042-05 58181-3042 Lomustine Gleostine 100.0 mg/1 Chemotherapy Alkylating Agent Nitrosourea Oral Aug. 18, 2014 In Use
59923-0707-05 59923-0707 temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jan. 25, 2019 In Use
59923-0708-14 59923-0708 temozolomide TEMOZOLOMIDE 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jan. 25, 2019 In Use
63539-0486-03 63539-0486 palbociclib Ibrance 100.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
72064-0110-30 72064-0110 avapritinib Ayvakit 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Oral Jan. 9, 2020 In Use
00093-5742-19 00093-5742 Cyclosporine Cyclosporine Modified 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral June 1, 2015 Jan. 31, 2023 No Longer Used
00093-5742-65 00093-5742 Cyclosporine Cyclosporine Modified 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral June 1, 2015 Jan. 31, 2023 No Longer Used
51991-0376-05 51991-0376 IMATINIB MESYLATE IMATINIB MESYLATE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 8, 2019 March 31, 2023 No Longer Used
51991-0376-17 51991-0376 IMATINIB MESYLATE IMATINIB MESYLATE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 8, 2019 March 31, 2023 No Longer Used
51991-0376-90 51991-0376 IMATINIB MESYLATE IMATINIB MESYLATE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Feb. 8, 2019 March 31, 2023 No Longer Used
62559-0922-14 62559-0922 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 16, 2020 Feb. 28, 2023 No Longer Used
62559-0922-51 62559-0922 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 16, 2020 Feb. 28, 2023 No Longer Used
00003-0852-11 00003-0852 Dasatinib Sprycel 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral June 3, 2009 Jan. 26, 2011 In Use
00003-0852-22 00003-0852 Dasatinib Sprycel 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 30, 2008 In Use
00078-0241-15 00078-0241 Cyclosporine Sandimmune 100.0 mg/1 Ancillary Therapy Immunomodulator Calcineurin Inhibitor Oral March 2, 1990 In Use

Found 10,000 results in 8 milliseconds — Export these results